Lumos Diagnostics develops and manufactures rapid point-of-care diagnostic tests, such as FebriDx and ViraDx, which utilize fingerstick blood samples to differentiate between bacterial and viral infections. These solutions provide healthcare professionals with timely and accurate information to improve patient management and reduce unnecessary antibiotic use.
Funding
$17.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In primary care settings, differentiating between bacterial and viral infections often relies on clinical assessment alone, leading to uncertainty and potential overuse of antibiotics. Traditional laboratory tests can be time-consuming, delaying appropriate treatment decisions and contributing to antibiotic resistance.
Solution
Lumos Diagnostics develops and manufactures rapid point-of-care diagnostic tests, such as FebriDx and ViraDx, that enable clinicians to quickly distinguish between bacterial and viral infections using a fingerstick blood sample. These tests provide actionable information in real-time, facilitating informed decisions about antibiotic prescriptions and improving patient management. Lumos also offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.
Target Audience
The primary target audience includes healthcare professionals in primary care settings who require rapid and accurate diagnostic tools to differentiate between bacterial and viral infections, as well as companies seeking custom development and manufacturing of point-of-care diagnostic tests.
Features
- FebriDx: A rapid point-of-care test that aids in differentiating between bacterial and non-bacterial infections using a fingerstick blood sample.
- ViraDx: A rapid point-of-care test that simultaneously detects acute respiratory infections caused by COVID-19, Influenza A, and Influenza B viruses.
- Custom assay development for point-of-care tests.
- Manufacturing services for point-of-care tests and proprietary digital reader platforms.
- Strategic innovation services, including initial evaluation of point-of-care diagnostic test product concepts.
- Development and manufacturing transfer services, including customization and integration of Lumos digital reader technology.
- Clinical and product validation and commercial-scale manufacturing of test strips and readers.
- Medical, quality, and regulatory affairs support throughout product development and commercialization.